These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 25559688)

  • 1. Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients.
    Duchnowska R; Jassem J; Goswami CP; Dundar M; Gökmen-Polar Y; Li L; Woditschka S; Biernat W; Sosińska-Mielcarek K; Czartoryska-Arłukowicz B; Radecka B; Tomasevic Z; Stępniak P; Wojdan K; Sledge GW; Steeg PS; Badve S
    J Neurooncol; 2015 Mar; 122(1):205-16. PubMed ID: 25559688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological significance of β -tubulin isotype III gene expression in breast cancer patients.
    He Q; Peng B; Zhuang D; Xiao L; Zheng L; Fan Z; Zhu J; Xu B; Xu C; Zhao J; Wu L; Zhou P; Hou L; Yu F; Zhao G
    Cancer Biomark; 2015; 15(6):823-31. PubMed ID: 26406408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival.
    Tarhan MO; Demir L; Somali I; Yigit S; Erten C; Alacacioglu A; Ellidokuz H; Seseogullari O; Kucukzeybek Y; Can A; Dirican A; Bayoglu V; Akyol M
    Clin Exp Metastasis; 2013 Feb; 30(2):201-13. PubMed ID: 22915160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating microRNA-based screening tool for breast cancer.
    Frères P; Wenric S; Boukerroucha M; Fasquelle C; Thiry J; Bovy N; Struman I; Geurts P; Collignon J; Schroeder H; Kridelka F; Lifrange E; Jossa V; Bours V; Josse C; Jerusalem G
    Oncotarget; 2016 Feb; 7(5):5416-28. PubMed ID: 26734993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-4728-3p could act as a marker of HER2 status.
    Li H; Zhou X; Zhu J; Cheng W; Zhu W; Shu Y; Liu P
    Cancer Biomark; 2015; 15(6):807-14. PubMed ID: 26406406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ESPL1 is a candidate oncogene of luminal B breast cancers.
    Finetti P; Guille A; Adelaide J; Birnbaum D; Chaffanet M; Bertucci F
    Breast Cancer Res Treat; 2014 Aug; 147(1):51-9. PubMed ID: 25086634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
    Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
    Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
    Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
    Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
    Müller V; Gade S; Steinbach B; Loibl S; von Minckwitz G; Untch M; Schwedler K; Lübbe K; Schem C; Fasching PA; Mau C; Pantel K; Schwarzenbach H
    Breast Cancer Res Treat; 2014 Aug; 147(1):61-8. PubMed ID: 25086636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis.
    Niikura N; Hayashi N; Masuda N; Takashima S; Nakamura R; Watanabe K; Kanbayashi C; Ishida M; Hozumi Y; Tsuneizumi M; Kondo N; Naito Y; Honda Y; Matsui A; Fujisawa T; Oshitanai R; Yasojima H; Tokuda Y; Saji S; Iwata H
    Breast Cancer Res Treat; 2014 Aug; 147(1):103-12. PubMed ID: 25106661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
    Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R
    Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.
    Ulas A; Kos T; Avci N; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
    Asian Pac J Cancer Prev; 2015; 16(4):1643-9. PubMed ID: 25743846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical prediction of brain metastases in patients with advanced breast cancer: the role of Rad51.
    Sosińska-Mielcarek K; Duchnowska R; Winczura P; Badzio A; Majewska H; Lakomy J; Pęksa R; Pieczyńska B; Radecka B; Dębska S; Biernat W; Jassem J
    Breast; 2013 Dec; 22(6):1178-83. PubMed ID: 24060578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct Characteristics and Metastatic Behaviors of Late Recurrence in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: A Single Institute Experience of More Than 10 Years.
    Chen X; Fan Y; Xu B
    Clin Breast Cancer; 2018 Dec; 18(6):e1353-e1360. PubMed ID: 30201586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression.
    Balduzzi A; Bagnardi V; Rotmensz N; Dellapasqua S; Montagna E; Cardillo A; Viale G; Veronesi P; Intra M; Luini A; Pruneri G; Mastropasqua G; Goldhirsch A; Colleoni M
    Clin Breast Cancer; 2014 Aug; 14(4):258-64. PubMed ID: 24325948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.
    Xu C; Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Murakami K; Okumura Y; Yamaguchi L; Fujiki Y; Iwase H
    Breast Cancer; 2014 Jul; 21(4):482-90. PubMed ID: 22968628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary and secondary distant metastatic breast cancer: two sides of the same coin.
    Güth U; Magaton I; Huang DJ; Fisher R; Schötzau A; Vetter M
    Breast; 2014 Feb; 23(1):26-32. PubMed ID: 24215983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 Codon 655 (Ile/Val) Polymorphism and Breast Cancer in Austrian Women.
    Watrowski R; Castillo-Tong DC; Wolf A; Schuster E; Fischer MB; Speiser P; Zeillinger R
    Anticancer Res; 2015 Nov; 35(11):5901-4. PubMed ID: 26504013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Location of Receipt of Initial Treatment and Outcomes in Long-Term Breast Cancer Survivors.
    Sinha AK; Patel JR; Shen Y; Ueno NT; Giordano SH; Tripathy D; Lopez DS; Barcenas CH
    PLoS One; 2017; 12(1):e0170081. PubMed ID: 28085940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.